Long-Term Safety and Efficacy of a Once-Daily Formulation of Alfuzosin 10 mg in Patients with Symptomatic Benign Prostatic Hyperplasia: Open-Label Extension Study

By van Kerrebroeck P.   Jardin A.   van Cangh P.   Laval K.U.   The ALFORTI Study Group  

European Urology, Vol. 41, Iss. 1, 2002-01 ,pp. : 54-61

Elsevier

Access to resources Recommend Favorite

Long-Term Evaluation of Tamsulosin in Benign Prostatic Hyperplasia: Placebo-Controlled, Double-Blind Extension of Phase III Trial - risk factors and concomitance with hypertension

By Lepor H.  

Urology, Vol. 51, Iss. 6, 1998-06 ,pp. : 901-906

Elsevier

Access to resources Recommend Favorite

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia

By Elhilali M.M.   Ramsey E.W.   Barkin J.   Casey R.W.   Boake R.C.   Beland G.   Fradet Y.   Trachtenberg J.   Orovan W.L.   Schick E.   Klotz L.H.  

Urology, Vol. 47, Iss. 3, 1996-03 ,pp. : 335-342

Elsevier

Access to resources Recommend Favorite

Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia

By Lowe F.C.   McConnell J.D.   Hudson P.B.   Romas N.A.   Boake R.   Lieber M.   Elhilali M.   Geller J.   Imperto-McGinely J.   Andriole G.L.   Bruskewitz R.C.   Walsh P.C.   Bartsch G.   Nacey J.N.   Shah S.   Pappas F.   Ko A.   Cook T.   Stoner E.   Waldstreicher J.   FINASTERIDE STUDY GROUP  

Urology, Vol. 61, Iss. 4, 2003-04 ,pp. : 791-796

Elsevier

Access to resources Recommend Favorite

Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia

By Lepor H.  

Urology, Vol. 45, Iss. 3, 1995-03 ,pp. : 406-413

Elsevier

Access to resources Recommend Favorite